Dr Gary Waanders at Healthcare Director at Zeus Capital chats with DirectorsTalk about Motif Bio Plc (LON:MTFB) it’s lead product iclaprim, why it’s special, the trials, what it might achieve at peak sales, fair value estimate for the company and how Motif’s current market cap compares to other antibiotic developers with late stage assets.
Motif Bio Plc is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.
